Skip Navigation Links
SEARCH  



 
Bookmark and Share
RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19
Positive U.S. Phase 2 safety and efficacy data for opaganib, a leading novel, oral, dual-mechanism drug candidate for moderate-to-severe COVID-19, presented at the World Microbe Forum Opaganib was associated w...

Full "IntellAsia: Resources" article




Disclaimer | Terms Of Use And Privacy Statement


© Metals News. All rights reserved.